Header Logo

Connection

LOIS M RAMONDETTA to Uterine Cervical Neoplasms

Back to Details
This is a "connection" page, showing publications LOIS M RAMONDETTA has written about Uterine Cervical Neoplasms.
LOIS M RAMONDETTA
Connection Strength
3.997
Uterine Cervical Neoplasms
  1. Mean direct medical care costs associated with cervical cancer for commercially insured patients in Texas. Gynecol Oncol. 2017 04; 145(1):108-113.
    View in: PubMed
    Score: 0.259
  2. Avoidable tragedies: Disparities in healthcare access among medically underserved women diagnosed with cervical cancer. Gynecol Oncol. 2015 Dec; 139(3):500-5.
    View in: PubMed
    Score: 0.237
  3. Retrospective review of symptoms and palliative care interventions in women with advanced cervical cancer. Gynecol Oncol. 2015 Dec; 139(3):553-8.
    View in: PubMed
    Score: 0.236
  4. What is the appropriate approach to treating women with incurable cervical cancer? J Natl Compr Canc Netw. 2013 Mar 01; 11(3):348-55.
    View in: PubMed
    Score: 0.197
  5. Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study. Gynecol Oncol. 2012 Dec; 127(3):451-5.
    View in: PubMed
    Score: 0.191
  6. Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings. Cancer. 2011 May 01; 117(9):1928-34.
    View in: PubMed
    Score: 0.168
  7. Ethnic disparities in cervical cancer survival among Medicare eligible women in a multiethnic population. Int J Gynecol Cancer. 2009 Jan; 19(1):13-20.
    View in: PubMed
    Score: 0.148
  8. Social factors affecting treatment of cervical cancer: ethical issues and policy implications. Obstet Gynecol. 2008 Mar; 111(3):747-51.
    View in: PubMed
    Score: 0.139
  9. Advanced cervical cancer treatment in Harris County: pilot evaluation of factors that prevent optimal therapy. Gynecol Oncol. 2006 Nov; 103(2):547-53.
    View in: PubMed
    Score: 0.123
  10. Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring. Cancer Cell. 2023 11 13; 41(11):1945-1962.e11.
    View in: PubMed
    Score: 0.103
  11. Efficacy of a Smoking Cessation Intervention for Survivors of Cervical Intraepithelial Neoplasia or Cervical Cancer: A Randomized Controlled Trial. J Clin Oncol. 2023 05 20; 41(15):2779-2788.
    View in: PubMed
    Score: 0.099
  12. Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study. Gynecol Oncol. 2023 04; 171:141-150.
    View in: PubMed
    Score: 0.099
  13. Vulvar Cancer Incidence in the United States and its Relationship to Human Papillomavirus Vaccinations, 2001-2018. Cancer Prev Res (Phila). 2022 11 01; 15(11):777-784.
    View in: PubMed
    Score: 0.096
  14. Metagenomes of rectal swabs in larger, advanced stage cervical cancers have enhanced mucus degrading functionalities and distinct taxonomic structure. BMC Cancer. 2022 Sep 01; 22(1):945.
    View in: PubMed
    Score: 0.095
  15. Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers. Cancer Immunol Res. 2022 02; 10(2):259-271.
    View in: PubMed
    Score: 0.091
  16. ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer. Int J Gynecol Cancer. 2021 10; 31(10):1317-1325.
    View in: PubMed
    Score: 0.089
  17. Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation. Commun Biol. 2021 02 22; 4(1):237.
    View in: PubMed
    Score: 0.086
  18. Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062). Mol Cancer Ther. 2020 11; 19(11):2363-2370.
    View in: PubMed
    Score: 0.083
  19. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. Int J Gynecol Cancer. 2020 05; 30(5):596-601.
    View in: PubMed
    Score: 0.080
  20. Microbial Diversity and Composition Is Associated with Patient-Reported Toxicity during Chemoradiation Therapy for Cervical Cancer. Int J Radiat Oncol Biol Phys. 2020 05 01; 107(1):163-171.
    View in: PubMed
    Score: 0.079
  21. Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls. Gynecol Oncol. 2019 11; 155(2):237-244.
    View in: PubMed
    Score: 0.078
  22. Knowledge matters and?empowers: HPV vaccine advocacy among HPV-related cancer survivors. Support Care Cancer. 2020 May; 28(5):2407-2413.
    View in: PubMed
    Score: 0.077
  23. Cervical, Vaginal, and Vulvar Cancer Costs Incurred by the Medicaid Program in Publicly Insured Patients in Texas. J Low Genit Tract Dis. 2019 Apr; 23(2):102-109.
    View in: PubMed
    Score: 0.075
  24. Relationship Between Intent to Vaccinate and the Education and Knowledge of Human Papillomavirus Among Medical School Faculty and Students in Texas. Tex Med. 2019 Jan 01; 115(1):e1.
    View in: PubMed
    Score: 0.074
  25. Age-Structured Population Modeling of HPV-related Cervical Cancer in Texas and US. Sci Rep. 2018 09 25; 8(1):14346.
    View in: PubMed
    Score: 0.072
  26. Low Rate of Cervical Cancer Screening among Women with Hematologic Malignancies after Stem Cell Transplant. Biol Blood Marrow Transplant. 2018 05; 24(5):1094-1098.
    View in: PubMed
    Score: 0.069
  27. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017 Oct 07; 390(10103):1654-1663.
    View in: PubMed
    Score: 0.067
  28. Factors associated with grade 3 or 4 treatment-related toxicity in women with advanced or recurrent cervical cancer: an exploratory analysis of NRG Oncology/Gynecologic Oncology Group trials 179 and 204. Int J Gynecol Cancer. 2015 Feb; 25(2):303-8.
    View in: PubMed
    Score: 0.056
  29. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncol. 2015 Mar; 16(3):301-11.
    View in: PubMed
    Score: 0.056
  30. Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group. J Clin Oncol. 2014 Sep 01; 32(25):2744-9.
    View in: PubMed
    Score: 0.054
  31. Patient preferences for side effects associated with cervical cancer treatment. Int J Gynecol Cancer. 2014 Jul; 24(6):1077-84.
    View in: PubMed
    Score: 0.054
  32. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014 Feb 20; 370(8):734-43.
    View in: PubMed
    Score: 0.053
  33. Use of social media to conduct a cross-sectional epidemiologic and quality of life survey of patients with neuroendocrine carcinoma of the cervix: a feasibility study. Gynecol Oncol. 2014 Jan; 132(1):149-53.
    View in: PubMed
    Score: 0.051
  34. Risk of residual disease and invasive carcinoma in women treated for adenocarcinoma in situ of the cervix. Gynecol Oncol. 2013 Jun; 129(3):513-6.
    View in: PubMed
    Score: 0.049
  35. Anatomic location of PET-positive aortocaval nodes in patients with locally advanced cervical cancer: implications for surgical staging. Int J Gynecol Cancer. 2012 Sep; 22(7):1203-7.
    View in: PubMed
    Score: 0.048
  36. Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer. Pharmacotherapy. 2011 Mar; 31(3):280-97.
    View in: PubMed
    Score: 0.043
  37. Rate of para-aortic lymph node micrometastasis in patients with locally advanced cervical cancer. Gynecol Oncol. 2010 Dec; 119(3):422-5.
    View in: PubMed
    Score: 0.042
  38. Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2010 Dec; 119(3):531-7.
    View in: PubMed
    Score: 0.042
  39. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009 Oct 01; 27(28):4649-55.
    View in: PubMed
    Score: 0.039
  40. Concurrent chemoradiation in the routine management of patients with cervical cancer: does marital status matter? Int J Gynecol Cancer. 2009 Aug; 19(6):1107-12.
    View in: PubMed
    Score: 0.038
  41. Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment. Int J Radiat Oncol Biol Phys. 2008 Jan 01; 70(1):118-25.
    View in: PubMed
    Score: 0.034
  42. Clinical challenges presented by three simultaneous solid tumors. Gynecol Oncol. 2006 Dec; 103(3):1159-63.
    View in: PubMed
    Score: 0.032
  43. Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix. Gynecol Oncol. 2005 Jun; 97(3):840-4.
    View in: PubMed
    Score: 0.029
  44. Development of endometrial cancer after radiation treatment for cervical carcinoma. Obstet Gynecol. 2003 May; 101(5 Pt 1):941-5.
    View in: PubMed
    Score: 0.025
  45. A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation. Support Care Cancer. 2021 Jan; 29(1):213-222.
    View in: PubMed
    Score: 0.020
  46. Quantitative image analysis of MIB-1 reactivity in inflammatory, hyperplastic, and neoplastic endocervical lesions. Int J Gynecol Pathol. 1997 Jan; 16(1):15-21.
    View in: PubMed
    Score: 0.016
  47. Radiation-associated endometrial cancers are prognostically unfavorable tumors: a clinicopathologic comparison with 527 sporadic endometrial cancers. Gynecol Oncol. 2006 Dec; 103(3):948-51.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.